Interferon alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon alfa-2b treatment Article

Bramlette, Tracy B, Lawson, David H, Washington, Carl V et al. (2007). Interferon alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon alfa-2b treatment . DERMATOLOGIC SURGERY, 33(1), 11-16. 10.1111/j.1524-4725.2007.33001.x

cited authors

  • Bramlette, Tracy B; Lawson, David H; Washington, Carl V; Veledar, Emir; Johns, Barry R; Brisman, Stacey F; Abramova, Liana; Chen, Suephy C

sustainable development goals

authors

publication date

  • January 1, 2007

webpage

published in

keywords

  • ADJUSTED SURVIVAL ANALYSIS
  • AMERICAN JOINT COMMITTEE
  • BILATERAL PROPHYLACTIC MASTECTOMY
  • CANCER STAGING SYSTEM
  • COOPERATIVE-ONCOLOGY-GROUP
  • Dermatology
  • HIGH-RISK MELANOMA
  • Life Sciences & Biomedicine
  • PREFERENCES
  • QUALITY-OF-LIFE
  • RESECTED CUTANEOUS MELANOMA
  • Science & Technology
  • Surgery
  • THERAPY

Digital Object Identifier (DOI)

publisher

  • LIPPINCOTT WILLIAMS & WILKINS

start page

  • 11

end page

  • 16

volume

  • 33

issue

  • 1